Lilly Asia Ventures led a USD100m round in Shanghai-based Dizal Pharma, a joint venture between state-owned SDIC Fund Management, Swedish drugmaker AstraZeneca, and Zytz Partners that develops therapies for cancer and autoimmunity. New investors Sequoia Capital China, Trinity Innovation Fund, and Wuxi NewForce also participated in the round. Read more